Volume 17, Number 6—June 2011
Dispatch
Klebsiella pneumoniae Bacteremia and Capsular Serotypes, Taiwan
Table A2
Distribution and clinical characteristics of 133 patients with community-onset Klebsiella pneumoniae bacteremia caused by different serotypes, Taiwan*
| Characteristic | K1 (n = 36) | K2 (n = 22) | Non-K1/K2 (n = 75) | Univariate analysis (K1 vs. non–K1/K2) |
Univariate analysis (K2 vs. non– K1/K2) |
||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR 95% CI | p value | ||||
| Age, y | 60.6 ± 13.5 | 58.0 ± 15.6 | 63.7 ± 16.6 | 0.99 (0.96–1.01) | 0.33 | 0.98 (0.95–1.01) | 0.13 |
| M:F | 23:13 | 15:7 | 40:35 | 1.55 (0.68–3.51) | 0.30 | 1.88 (0.69–5.12) | 0.22 |
| Severity of disease (McCabe classification) | |||||||
| Nonfatal | 29 (80.6) | 18 (81.8) | 51 (68.0) | 1.95 (0.75–5.078) | 0.17 | 2.12 (0.65–6.94) | 0.22 |
| Ultimately fatal | 5 (13.9) | 3 (13.6) | 17 (22.7) | 0.55 (0.19–1.63) | 0.28 | 0.54 (0.14–2.04) | 0.36 |
| Rapidly fatal | 2 (5.5) | 1 (4.6) | 7 (9.3) | 0.57 (0.11–2.90) | 0.50 | 0.46 (0.05–3.98) | 0.48 |
| Pittsburgh bacteremia score | 2.5 ± 2.7 | 3.2 ± 3.7 | 3.8 ± 4.6 | 0.91 (0.81–1.03) | 0.13 | 0.97 (0.86–1.09) | 0.60 |
| Underlying illness, condition, or value | |||||||
| Diabetes mellitus | 17 (47.2) | 11 (50.0) | 31 (41.3) | 1.27 (0.57–2.83) | 0.56 | 1.42 (0.55–3.68) | 0.47 |
| End-stage renal disease | 1 (2.8) | 0 | 5 (6.7) | 0.40 (0.05–3.56) | 0.41 | NA | NA |
| Heart disease | 3 (8.3) | 5 (22.7) | 13 (17.3) | 0.43 (0.12–1.63) | 0.22 | 1.49 (0.44–4.49) | 0.57 |
| Stroke | 3 (8.3) | 3 (13.6) | 9 (12.0) | 0.67 (0.17–2.63) | 0.56 | 1.16 (0.29–4.71) | 0.84 |
| Active malignancy | 3 (8.3) | 1 (4.6) | 12 (16.0) | 0.48 (0.13–1.81) | 0.28 | 0.25 (0.03–2.04) | 0.20 |
| Liver cirrhosis | 3 (8.3) | 3 (13.6) | 9 (12.0) | 0.67 (0.17–2.63) | 0.56 | 1.16 (0.29–4.71) | 0.84 |
| Surgery within 3 mo | 2 (5.6) | 0 | 10 (13.3) | 0.38 (0.08–1.85) | 0.23 | NA | NA |
| CT within 3 mo | 1 (2.8) | 0 | 3 (4.0) | 0.69 (0.07–6.83) | 0.75 | NA | NA |
| Creatinine level, mg/dL | 1.7 ± 2.0 | 1.5 ± 1.2 | 1.9 ± 2.1 | 0.95 (0.77–1.18) | 0.66 | 0.86 (0.62–1.19) | 0.35 |
| Albumin level, g/dL† | 2.7 ± 0.6 | 2.6 ± 0.4 | 2.9 ± 0.6 | 0.63 (0.23–1.67) | 0.35 | 0.33 (0.09–1.27) | 0.11 |
| Type of infection | |||||||
| Primary bacteremia | 8 (22.2) | 5 (22.7) | 18 (24.0) | 0.91 (0.35–2.33) | 0.84 | 0.93 (0.30–2.88) | 0.90 |
| Respiratory tract | 3 (8.3) | 4 (18.2) | 12 (16.0) | 0.48 (0.13–1.81) | 0.28 | 1.17 (0.34–4.06) | 0.81 |
| Urinary tract | 2 (5.6) | 3 (13.6) | 17 (22.7) | 0.20 (0.04–0.92) | 0.039 | 0.54 (0.14–2.04) | 0.36 |
| Biliary tract | 3 (8.3) | 2 (9.1) | 20 (26.7) | 0.25 (0.07–0.91) | 0.035 | 0.28 (0.06–1.28) | 0.10 |
| Liver abscess | 18 (50.0) | 5 (22.7) | 6 (8.0) | 11.5 (3.99–33.20) | <0.001 | 3.38 (0.92–12.4) | 0.07 |
| Intraabdominal | 1 (2.8) | 2 (9.1) | 1 (1.3) | 2.1 (0.13–34.80) | 0.60 | 7.40 (0.64–85.82) | 0.11 |
| Soft tissue | 0 | 0 | 1 (1.3) | NA | NA | NA | NA |
| Meningitis | 1 (2.8) | 1 (4.6) | 0 | NA | NA | NA | NA |
| TTP, h | 13.6 ± 17.4 | 10.4 ± 3.0 | 15.6 ± 21.1 | 0.99 (0.97–1.02) | 0.62 | 0.97 (0.90–1.04) | 0.34 |
| TTP<7 h | 5 (13.9) | 2 (9.1) | 8 (10.7) | 1.35 (0.41–4.47) | 0.62 | 0.84 (0.34–2.09) | 0.71 |
| 14-d mortality rate | 3 (8.3) | 3 (13.6) | 13 (17.3) | 0.43 (0.12–1.63) | 0.22 | 0.75 (0.19–2.92) | 0.68 |
| In-hospital mortality rate | 5 (13.9) | 6 (27.3) | 21 (28.0) | 0.42 (0.14–1.21) | 0.11 | 0.96 (0.33–2.80) | 0.95 |
| ESBL-producing strain | 0 | 0 | 0 | NA | NA | NA | NA |
| Effective empirical agent | 31 (86.1) | 22 (100.0) | 72 (96.0) | 0.26 (0.06–1.15) | 0.08 | NA | NA |
*Values are mean ± SD or no. (%) unless otherwise indicated. OR, odds ratio; CI, confidence interval; NA, not applicable; CT, computed tomography; TTP, time to positive blood culture; ESBL, extended-spectrum β-lactamase.
†For K1 group, 24 patients; for K2 group, 25 patients; for non–K1/K2 group, 93 patients.
Page created: August 03, 2011
Page updated: August 03, 2011
Page reviewed: August 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.